Your session is about to expire
← Back to Search
GLP-1 Receptor Agonist
Phentermine-Topiramate for Obesity
Phase 3
Waitlist Available
Led By Andres J Acosta
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing if choosing weight loss medications based on individual body traits works better than picking them randomly. Participants with obesity will either get a medication chosen for them or one picked without considering their traits. The study will track their progress to see which method is more effective.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Total Body Weight
Secondary study objectives
Percentage of Responders
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention groupExperimental Treatment3 Interventions
Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
Group II: Control GroupActive Control4 Interventions
Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
2013
Completed Phase 4
~2680
Phentermine-Topiramate
2017
Completed Phase 3
~200
Naltrexone/bupropion
2017
Completed Phase 3
~200
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,289 Total Patients Enrolled
88 Trials studying Obesity
9,070 Patients Enrolled for Obesity
Andres J AcostaPrincipal InvestigatorMayo Clinic
Share this study with friends
Copy Link
Messenger